ペプチド薬物複合体の世界市場レポート 2025年

ペプチド薬物複合体の市場規模は、今後数年で急成長が見込まれます。2029年には年間平均成長率（CAGR）15.8％で66億米ドルに成長します。予測期間中の成長は、世界のがん罹患率の上昇、標的がん治療に対する需要の増加、ペプチドベースの医薬品候補のパイプラインの増加、個別化医療の拡大、併用療法に対する関心の高まりなどの要因に起因すると考えられます。予測期間を形成すると予想される主な動向には、ペプチド合成技術の向上、リンカー技術の進歩、部位特異的コンジュゲーション法の強化、腫瘍ターゲティング能力の向上、ペイロード選択の革新などがあります。

個別化治療に対する需要の高まりが、今後数年間のペプチド薬物複合体市場の成長を牽引すると予想されます。個別化治療とは、最も効果的な治療結果を得るために、個人特有の遺伝的体質、ライフスタイル、疾患の特徴に合わせて調整される治療法です。ゲノミクスの進歩により、特定の疾患マーカーが特定され、より正確で効果的な治療が可能になるため、このような傾向が強まっています。ペプチド薬物複合体の場合、個別化治療によって、患者固有の疾患バイオマーカーを標的とする特定のペプチドを選択することが可能になり、より正確で効果的なドラッグデリバリーが実現します。例えば、2024年2月、個別化医療連合（Personalized Medicine Coalition）は、FDAが2023年に希少疾患患者向けに16の新規カスタマイズ医薬品を認可したと報告しました。その結果、個別化治療に対する需要の高まりがペプチド薬物複合体市場の成長を加速させる構えです。

ペプチド薬物複合体市場の主要企業は、治療精度を向上させるため、腫瘍選択的ペプチド薬物複合体などの先進治療法の開発に注力しています。これらの治療法は、がん細胞に結合するように特別に設計されたペプチドを使用し、健康な組織への害を最小限に抑えながら、腫瘍に細胞毒性薬剤を直接送達することを可能にします。例えば、2025年3月、米国のがんバイオテクノロジー企業であるサイブレクサ・セラピューティクス社は、アルファレックス技術から得られた新たな前臨床データを発表しました。このデータは、強力な微小管阻害剤を腫瘍細胞に直接送達する、サイブレクサ社の抗原診断ペプチド薬物複合体（PDC）プラットフォームの有効性を強調するものでした。このアプローチは、腫瘍の成長を抑制するだけでなく、持続的な抗腫瘍免疫反応を引き起こします。この研究結果は、がん治療の進歩におけるサイブレクサ社の技術の可能性を強調するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のペプチド薬物複合体PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のペプチド薬物複合体市場：成長率分析
• 世界のペプチド薬物複合体市場の実績：規模と成長, 2019-2024
• 世界のペプチド薬物複合体市場の予測：規模と成長, 2024-2029, 2034F
• 世界のペプチド薬物複合体総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のペプチド薬物複合体市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 治療
• 診断
• 世界のペプチド薬物複合体市場：治療領域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍学
• 免疫学
• 感染症
• その他の治療分野
• 世界のペプチド薬物複合体市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内
• 皮下
• その他の投与経路
• 世界のペプチド薬物複合体市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 薬局
• その他のエンドユーザー
• 世界のペプチド薬物複合体市場、治療のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体（mAbs）
• 細胞傷害性薬剤
• 免疫調節薬
• 標的療法
• 世界のペプチド薬物複合体市場、診断のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 造影剤
• バイオマーカー標的剤
• 診断キット

第7章 地域別・国別分析

• 世界のペプチド薬物複合体市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のペプチド薬物複合体市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ペプチド薬物複合体市場：競合情勢
• ペプチド薬物複合体市場：企業プロファイル
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • BioNTech SE Overview, Products and Services, Strategy and Financial Analysis
  • Curium US LLC Overview, Products and Services, Strategy and Financial Analysis
  • ADC Therapeutics SA Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• PeptiDream Incorporated
• PepGen Corporation
• Theratechnologies Inc.
• Italfarmaco Societa per Azioni
• Protagonist Therapeutics Inc.
• Alteogen Inc.
• Metsera Inc.
• Zealand Pharma A/S
• Apellis Pharmaceuticals Inc.
• Angiochem Inc.
• Cybrexa Therapeutics Inc.
• Ambrx Inc.
• Oncopeptides Aktiebolag（AB）
• ProteinQure Incorporated
• Soricimed Biopharma Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ペプチド薬物複合体市場2029：新たな機会を提供する国
• ペプチド薬物複合体市場2029：新たな機会を提供するセグメント
• ペプチド薬物複合体市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Peptide drug conjugates (PDCs) are targeted treatments that combine peptides with cytotoxic drugs to enhance therapeutic precision. The peptide, which specifically binds to cell receptors, is conjugated with the drug, allowing it to target diseased cells, such as tumors, directly. This method improves the drug's stability, selectivity, and bioavailability, thereby boosting its therapeutic effectiveness while minimizing harm to healthy tissues.

The main types of peptide drug conjugates include therapeutic and diagnostic. A therapeutic peptide drug conjugate involves attaching a peptide to a drug, typically a cytotoxic agent, to target cancer cells or other diseased tissue directly. These PDCs are used in the treatment of oncology, immunology, infectious diseases, and more. They can be administered through various routes, including intravenous and subcutaneous, and are commonly used in hospitals, clinics, pharmacies, and other healthcare settings.

The peptide drug conjugate market research report is one of a series of new reports from The Business Research Company that provides peptide drug conjugate market statistics, including peptide drug conjugate industry global market size, regional shares, competitors with a peptide drug conjugate market share, detailed peptide drug conjugate market segments, market trends and opportunities, and any further data you may need to thrive in the peptide drug conjugate industry. This peptide drug conjugate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The peptide drug conjugates market size has grown rapidly in recent years. It will grow from $3.16 billion in 2024 to $3.68 billion in 2025 at a compound annual growth rate (CAGR) of 16.1%. The growth during the historic period can be attributed to several factors, including a favorable regulatory environment for biologics and peptides, an increase in orphan drug designations for peptide drugs, government incentives for rare disease treatments, the expanding biopharmaceutical sector, and rising global healthcare expenditure.

The peptide drug conjugates market size is expected to see rapid growth in the next few years. It will grow to $6.60 billion in 2029 at a compound annual growth rate (CAGR) of 15.8%. The growth during the forecast period can be attributed to factors such as the rising global prevalence of cancer, increasing demand for targeted cancer therapies, a growing pipeline of peptide-based drug candidates, the expansion of personalized medicine, and rising interest in combination therapies. Key trends expected to shape the forecast period include improvements in peptide synthesis techniques, advancements in linker technologies, enhanced site-specific conjugation methods, better tumor targeting capabilities, and innovations in payload selection.

The increasing demand for personalized treatments is expected to drive the growth of the peptide drug conjugates market in the coming years. Personalized treatments are therapies tailored to an individual's unique genetic makeup, lifestyle, and disease characteristics to achieve the most effective outcomes. This rise is driven by advancements in genomics, which help identify specific disease markers, enabling more precise and effective therapies. In the case of peptide drug conjugates, personalized treatments allow for the selection of specific peptides that target unique disease biomarkers in patients, ensuring more precise and effective drug delivery. For example, in February 2024, the Personalized Medicine Coalition reported that the FDA authorized 16 novel customized medicines for patients with rare disorders in 2023, a significant increase from the six authorized in 2022. As a result, the growing demand for personalized treatments is poised to accelerate the growth of the peptide drug conjugates market.

Leading companies in the peptide drug conjugates market are concentrating on developing advanced treatment options, such as tumor-selective peptide drug conjugates, to improve treatment precision. These therapies use peptides specifically engineered to bind to cancer cells, allowing for the direct delivery of cytotoxic agents to tumors while minimizing harm to healthy tissue. For example, in March 2025, Cybrexa Therapeutics, a US-based oncology biotechnology company, shared new preclinical data from its alphalex technology. The data highlighted the effectiveness of Cybrexa's antigen-agnostic peptide-drug conjugate (PDC) platform in delivering powerful microtubule inhibitors directly to tumor cells. This approach not only suppresses tumor growth but also triggers a lasting anti-tumor immune response. The findings underscore the potential of Cybrexa's technology in advancing cancer treatment.

In May 2023, Bayer AG, a Germany-based pharmaceutical company, entered into a strategic collaboration with Bicycle Therapeutics to develop novel radioconjugates targeting various oncology indications. Through this partnership, Bicycle Therapeutics will leverage its proprietary phage display platform to identify and optimize highly selective bicyclic peptides. Bayer will lead the preclinical and clinical development, as well as oversee manufacturing and commercialization efforts. The goal is to create targeted radiotherapy solutions that address critical gaps in cancer treatment. Bicycle Therapeutics is a UK-based company specializing in the development of peptide drug conjugates designed for precision oncology applications.

Major players in the peptide drug conjugates market are AstraZeneca PLC, Novartis AG, BioNTech SE, Curium US LLC, ADC Therapeutics SA, PeptiDream Incorporated, PepGen Corporation, Theratechnologies Inc., Italfarmaco Societa per Azioni, Protagonist Therapeutics Inc., Alteogen Inc., Metsera Inc., Zealand Pharma A/S, Apellis Pharmaceuticals Inc., Angiochem Inc., Cybrexa Therapeutics Inc., Ambrx Inc., Oncopeptides Aktiebolag (AB), ProteinQure Incorporated, Soricimed Biopharma Inc., Esperance Pharmaceuticals Inc., Adcytherix SA, and Araris Biotech AG.

North America was the largest region in the peptide drug conjugates market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in peptide drug conjugates report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the peptide drug conjugates market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The peptide drug conjugates market consists of revenues earned by entities by providing services such as conjugation services, preclinical testing, formulation development, target discovery, and validation. The market value includes the value of related goods sold by the service provider or included within the service offering. The peptide drug conjugates market also includes sales of peptide payload linkers, synthetic peptides, peptide targeting ligands, and drug delivery systems. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Peptide Drug Conjugates Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on peptide drug conjugates market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for peptide drug conjugates ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The peptide drug conjugates market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Therapeutic; Diagnostic
• 2) By Therapy Area: Oncology; Immunology; Infectious Diseases; Other Therapy Areas
• 3) By Route of Administration: Intravenous; Subcutaneous; Other Routes Of Administration
• 4) By End User: Hospitals; Clinics; Pharmacies; Other End Users
• Subsegments:
• 1) By Therapeutic: Monoclonal Antibodies (mAbs); Cytotoxic Agents; Immunomodulatory Agents; Targeted Therapies
• 2) By Diagnostic: Imaging Agents; Biomarker Targeting Agents; Diagnostic Kits
• Companies Mentioned: AstraZeneca PLC; Novartis AG; BioNTech SE; Curium US LLC; ADC Therapeutics SA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Peptide Drug Conjugates Market Characteristics

3. Peptide Drug Conjugates Market Trends And Strategies

4. Peptide Drug Conjugates Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Peptide Drug Conjugates Growth Analysis And Strategic Analysis Framework

• 5.1. Global Peptide Drug Conjugates PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Peptide Drug Conjugates Market Growth Rate Analysis
• 5.4. Global Peptide Drug Conjugates Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Peptide Drug Conjugates Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Peptide Drug Conjugates Total Addressable Market (TAM)

6. Peptide Drug Conjugates Market Segmentation

• 6.1. Global Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Therapeutic
• Diagnostic
• 6.2. Global Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Immunology
• Infectious Diseases
• Other Therapy Areas
• 6.3. Global Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Subcutaneous
• Other Routes Of Administration
• 6.4. Global Peptide Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Pharmacies
• Other End Users
• 6.5. Global Peptide Drug Conjugates Market, Sub-Segmentation Of Therapeutic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies (mAbs)
• Cytotoxic Agents
• Immunomodulatory Agents
• Targeted Therapies
• 6.6. Global Peptide Drug Conjugates Market, Sub-Segmentation Of Diagnostic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Imaging Agents
• Biomarker Targeting Agents
• Diagnostic Kits

7. Peptide Drug Conjugates Market Regional And Country Analysis

• 7.1. Global Peptide Drug Conjugates Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Peptide Drug Conjugates Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Peptide Drug Conjugates Market

• 8.1. Asia-Pacific Peptide Drug Conjugates Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Peptide Drug Conjugates Market

• 9.1. China Peptide Drug Conjugates Market Overview
• 9.2. China Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Peptide Drug Conjugates Market

• 10.1. India Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Peptide Drug Conjugates Market

• 11.1. Japan Peptide Drug Conjugates Market Overview
• 11.2. Japan Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Peptide Drug Conjugates Market

• 12.1. Australia Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Peptide Drug Conjugates Market

• 13.1. Indonesia Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Peptide Drug Conjugates Market

• 14.1. South Korea Peptide Drug Conjugates Market Overview
• 14.2. South Korea Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Peptide Drug Conjugates Market

• 15.1. Western Europe Peptide Drug Conjugates Market Overview
• 15.2. Western Europe Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Peptide Drug Conjugates Market

• 16.1. UK Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Peptide Drug Conjugates Market

• 17.1. Germany Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Peptide Drug Conjugates Market

• 18.1. France Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Peptide Drug Conjugates Market

• 19.1. Italy Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Peptide Drug Conjugates Market

• 20.1. Spain Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Peptide Drug Conjugates Market

• 21.1. Eastern Europe Peptide Drug Conjugates Market Overview
• 21.2. Eastern Europe Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Peptide Drug Conjugates Market

• 22.1. Russia Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Peptide Drug Conjugates Market

• 23.1. North America Peptide Drug Conjugates Market Overview
• 23.2. North America Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Peptide Drug Conjugates Market

• 24.1. USA Peptide Drug Conjugates Market Overview
• 24.2. USA Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Peptide Drug Conjugates Market

• 25.1. Canada Peptide Drug Conjugates Market Overview
• 25.2. Canada Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Peptide Drug Conjugates Market

• 26.1. South America Peptide Drug Conjugates Market Overview
• 26.2. South America Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Peptide Drug Conjugates Market

• 27.1. Brazil Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Peptide Drug Conjugates Market

• 28.1. Middle East Peptide Drug Conjugates Market Overview
• 28.2. Middle East Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Peptide Drug Conjugates Market

• 29.1. Africa Peptide Drug Conjugates Market Overview
• 29.2. Africa Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Peptide Drug Conjugates Market Competitive Landscape And Company Profiles

• 30.1. Peptide Drug Conjugates Market Competitive Landscape
• 30.2. Peptide Drug Conjugates Market Company Profiles
  • 30.2.1. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. BioNTech SE Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Curium US LLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. ADC Therapeutics SA Overview, Products and Services, Strategy and Financial Analysis

31. Peptide Drug Conjugates Market Other Major And Innovative Companies

• 31.1. PeptiDream Incorporated
• 31.2. PepGen Corporation
• 31.3. Theratechnologies Inc.
• 31.4. Italfarmaco Societa per Azioni
• 31.5. Protagonist Therapeutics Inc.
• 31.6. Alteogen Inc.
• 31.7. Metsera Inc.
• 31.8. Zealand Pharma A/S
• 31.9. Apellis Pharmaceuticals Inc.
• 31.10. Angiochem Inc.
• 31.11. Cybrexa Therapeutics Inc.
• 31.12. Ambrx Inc.
• 31.13. Oncopeptides Aktiebolag (AB)
• 31.14. ProteinQure Incorporated
• 31.15. Soricimed Biopharma Inc.

32. Global Peptide Drug Conjugates Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Peptide Drug Conjugates Market

34. Recent Developments In The Peptide Drug Conjugates Market

35. Peptide Drug Conjugates Market High Potential Countries, Segments and Strategies

• 35.1 Peptide Drug Conjugates Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Peptide Drug Conjugates Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Peptide Drug Conjugates Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer